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El8051 Endothelin-AReceptorAntagonisminRatawithMyocardialInfarctionendFailura
J.M. Pfeffer, P.V.Finn, M.A. Pfeffer. Harvard Medical School, Btigharn &
Women’s Hospital, Boston, MA, USA
Endothelin is a potent vasoconstricfor which has been shown to be in-
creased in heart failure. We hypothesized that long-term administration of
the endothelin-A receptor antagonist, ETA (A-127722 Abbott), might favor-
ably impact LV remodeling and the development of heart failure in rats with
myooardial infarction and elevated endothelin levels. Female Wister rats
underwent coronay artery ligation, followed by 6 weeks of therapy with
ETA(0.0S mg/ml drinking water). Left ventricular and systemic arterial pres-
sures, peak pressure generating capacity (aortic occlusion), and ventricular
volumes (passive pressure-volume curves) were obtained in 46 animals [ve-
hicle(VEH): 5sham, IS Ml (31.4 +2.3%); ETA:Ssham, 15 Ml (36.1 *2.4%)].
Infarotsize was determined by planimetry of histologic sections. Treatment of
Ml: 1) reduced LVsystolic and systemic pressures but not LVfilling pressure;
2) reduoed peak LVSR 3) shifted the pressure-volume curve rightward; and
4) increased the LVvolume-to-mass ratio, eethe increase in volume was not
countered by an increase in mass (VEH, 0.72 + 0.02; ETA, 0.74 + 0.02 g)
“p< 0.05.
LVSP LVEDP MAP PLVSP VOL120 VOUM20
(mmHg) LVEDP (mmHg) (mmHg) (mVkg) (ml/g)
VEH 129 l 3 13.2 +3,2 112 +3 207 + 6 2,36 & 0.12 0.92 +0.04
ETA 114 +3* 14.3 l 3.1 98 &3* 188 &7* 2.92 +0.188 1.11 +0.05”
Endothelin-A antagonism in rats with myocardial infarction did not ben-
eficially alter LV remodeling despite a reduction in LV systolic, but not end-
diastolic, and systemic arterial pressures.
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G.W. Moe, G. Naik, A. Albernez, R.J. Howard, D. Stewart. Univereityof
Toronto, Toronto, On, Canada
The model of pacing-induced heart failure (PHF) is characterized by signifi-
cant biatrial but not LV hypertrophy. Endothelin-1 (ET-1) is a potent trophic
and vasoactive peptide. Although plasma ET-1is increased in pHF,the tissue
profile of cardiac ET-1 has not been examined. We therefore measured ET-1
in the 4 cardiac chambers in 9 control (C) and 11dogs with PHFafter 3weeks
pacing. Date (x+ SE) of ET-1 from LV,LA, RA, RV (frnol/g) are shown.
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In pHF, ET-1 level was elevated in LV but not in LA, RA or RV,despite a
marked increase in RAP and PCWP (15 + 3 vs 7 + 2 mmHg and 31 + 5 vs
9 + 2 mmHg, respectively, pHF vs C, both p c 0.01). Echo-derived LV mass
(2.7 + 0.5 vs 2.S + 0.5 @kg, NS) was unchanged despite increased ET-1.
LA and RA weights were increased (0.19 + 0.05 vs 0.09 + 0.03 g/kg and
0.15 + 0.04 vs 0.12 + 0.01 g/kg, both p < 0.05) despite unchanged ET-1.
Therefore, in pacing-induced HF, there is a selective activation of ET-1 in
LV. Furthermore, the discordance between ET-1 activation and hypertrophy
suggest that ET-1 does not induce cardiac remodeling in this model,
[805+1Adrenomedu,,inintha~vo,utionof~~Perimenta,
HeartFailure
M. Jougasaki, T.L. Stevens, D.D. Borgeson, A. Luchner, J.C. Burnett Jr..
Mayo Clinic, RochesteL MN, USA
Adrenomedullin (ADM) is a newly discovered vasoacfive and natriuretic pep-
tide which may play an important role in the cardiovascular regulation. It is
known that circulating ADM is increased in human congestive heart failure
(CHF) and its immunoreactivity is increased in failing human ventricles. The
present study was designed to extend previous investigations and establish
the plasma concentration, cardiorenal tissue concentration and immunohis-
tochemical bcelization of ADM in normal dogs and dogs with experimental
progressive left ventricular dysfunction (PLVD) produced by 36 days of rapid
ventricular pacing. PLVD resulted in significant decreases in left ventricu-
lar ejectiort fraction, arterial pressure and cardiac output with increases in
cardiac filling pressure and systemic vascular resistance. Plasma ADM con-
centration was 5.6 + 0.4 p~ml (n= 9) in normal dogs, and increased to 14.5
+ 2.5 pgfml (n = 9, p c 0.05 vs normal) in PLVD dogs. Although no significant
difference was observed in atrial tissue ADM between normals (859 + 165
p@9)and PLVD (688+ 124 pg/g), ventricular tissue ADM was significantly
increesed in PLVD dogs (279 + 53 pg/g, p < 0.05) as compared with the
normal dogs (134 & 32 pg/g). Renal ADM increased in accordance with the
evolution of CHF (185 +26 to 213 +37 pg/g, p < 0.05). lmmunohistochem-
icel examination revealed positive immunostaining within the myocytes in
troth atria and ventricles of both groups. Although there were no significant
difference in the intensity of immunoreactivity between normal and PLVD
atria, ADM immunoreactivity was significantly more intense in the ventricular
myocytes from failing hearts. ADM immunoreactivity was observed in the
glomerulus and distal tubules in the kidney and it was increased in PLVD
dogs as compared with the normal dogs. The present study demonstrates
that circulating, renal and ventricular ADM is activated in the progression
of CHF, and provides insights in a new vasodilating and natriuretic peptide
system in the progression of CHF.
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M. Argenziano, D.A. Dean, N. Moezami, H.M. Spotnitz, E.A. Rose,
D. Burkhoff, M.C. Oz, M.L. Dickstein. Columbia UniversiM New York, NY
USA
Background: Inhaled nitric oxide (NOI) is a selective pulmona~ vasodilator.
However, increases in left ventricular end-diastolic pressure (LVEDP) dur-
ing clinical use of NOi have raised concerns that NOi may be a negative
inotrope. We studied myocerdial effects of NOi in a porcine model of con-
gestive heart failure (CHF). Mathods: After induction of CHF in 6 pigs by
rapid ventricular pacing, aortic, pulmona~ artery (PAP) and LV pressure, PA
flow, and LV volume (conductance) were recorded during transient preioad
reduction, at baseline and after administration of NOi in concentrations of 20
and 40 ppm. Contractility was assessed by end-systolic pressure-volume re-
lationships (ESPVR) and preload-recruiteble stroke work (PRSW). Diastolic
properties were determined by end-diastolic pressure-volume relationships
(EDPVR) and the isovolumic pressure decay time constant (T). Resu/ta:
Baseline hemodynamics reflected CHF and pulmonary hypertension, and
NOI induced significant reductions in PAP and pulmonay vascular resis-
tance (PVR) (table). While LVEDP increaaed during NOi therapy, there were
no changes in ESPVR, PRSW,T, or EDPVR (VIO).Conclusions.’In a porcine
model of CHF and pulmonary hypertension, NOI reduced PAP and PVR but
did not alter indices of myocardial performance. NOi-induced increases in
LVEDPare therefore not due to direct myocardial effects, but maybe related
to increases in volume delivery to the left heari due to reduced PVR.
Parameter Baseline NO 20 ppm NO 40 ppm
LVEDP (mmHa) 16.S+ 3.5 1s.1 * 3.1 19.1 * 3.4*
CO (Urnin) “
PAP (mmHg)
PVR (Woods)
ESPVR (Ees)
ESPVR (Vo)
PRSW (k4w)
PRSW (Vo)
T keC-l)
2.9 & 0.6
34,7 * 3.1
6.8* 1.7
5.7* 2.1
39+ 13
45.6 + 13.2
57+ 12
58+ 6
2.7 + 0.7
29.5 + 2.2*’
4.5 * 1.0
5.9 * 2.1
47• 12
43.S i 11.8
61 * 11
60+ 5
2.4 + 0.5
29.0 + 2.3**
3.9 * 1.2*
5.6 * 2.3
47 i 14
37.4 * 8.6
60+ 16
59 t 6
V1~ (ml) 102 * 19 105 *21 107 + 23
“v <0.05 vs. baseline;““ p <0.01 vs. baseline (ANOVA); mean = SEM
